Onalabs, a Spanish deep-tech startup developing continuous health monitoring solutions through sweat analysis, has closed a Series A financing round worth more than €9.3 million. The funding was led by Sociedad Española para la Transformación Tecnológica (SETT), the Spanish Society for Technological Transformation.
The capital injection marks a significant milestone for the company as it moves to accelerate the deployment of its non-invasive health monitoring platform across European markets. Onalabs’ technology leverages sweat-based diagnostics to provide continuous insight into users’ health status without requiring traditional invasive testing methods.
Expanding Market Reach
The company plans to deploy the fresh capital toward scaling its continuous health-monitoring solutions and expanding its market reach throughout Europe. This growth phase comes as demand increases for alternative diagnostic approaches that reduce friction for patients while providing clinically relevant data.
Sweat analysis represents an emerging frontier in non-invasive health diagnostics. Unlike conventional blood tests or laboratory procedures, sweat-based monitoring offers potential advantages in accessibility and user convenience, particularly for applications requiring frequent or continuous measurement of health parameters.
Onalabs’ approach aligns with broader trends in the European healthtech sector, where investors and entrepreneurs increasingly focus on technologies that can democratize health monitoring and make diagnostic information more readily available to wider populations.
Strategic Backing
SETT’s decision to lead the funding round underscores growing institutional interest in Spanish deep-tech ventures, particularly those addressing significant healthcare challenges. The organization’s involvement suggests confidence in both Onalabs’ technical approach and its commercial potential across European healthcare systems.
The timing of this funding round reflects broader momentum in the European startup ecosystem around preventive health technologies and continuous monitoring solutions. As healthcare systems across the continent grapple with chronic disease management and aging populations, companies offering innovative diagnostic approaches have attracted increasing investor attention.
The capital will enable Onalabs to strengthen its technical infrastructure, expand its team, and pursue regulatory pathways necessary for broader market adoption. The company’s focus on non-invasive solutions positions it favorably within current healthcare trends emphasizing patient comfort and accessibility.
European Context
Spain’s startup ecosystem has gained prominence in recent years, with increasing venture capital activity and international recognition for innovation in sectors ranging from software to deep-tech. Healthtech remains a particularly active area, with Spanish founders developing solutions addressing everything from rare diseases to chronic condition management.
This investment in Onalabs reflects confidence from institutional Spanish investors in the country’s capacity to develop world-class healthcare technologies. As European markets increasingly prioritize alternatives to traditional diagnostic methods, companies like Onalabs demonstrate how local deep-tech talent can address gaps in global healthcare innovation.